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Mutations in the MPV17 gene are associated with hepatocerebral form of mitochondrial
depletion syndrome. The mechanisms through which MPV17 mutations cause
respiratory chain dysfunction and mtDNA depletion is still unclear. The MPV17 gene
encodes an inner membrane mitochondrial protein that was recently described to
function as a non-selective channel. Although its exact function is unknown, it is thought
to be important in the maintenance of mitochondrial membrane potential (19m). To
obtain more information about the role of MPV17 in human disease, we investigated
the effect of MPV17 knockdown and of selected known MPV17 mutations associated
with MPV17 disease in vitro. We used different approaches in order to evaluate the
cellular consequences of MPV17 deficiency. We found that lower levels of MPV17
were associated with impaired mitochondrial respiration and with a quiescent energetic
metabolic profile. All the mutations studied destabilized the protein, resulting in reduced
protein levels. We also demonstrated that different mutations caused different cellular
abnormalities, including increased ROS production, decreased oxygen consumption,
loss of 19m, and mislocalization of MPV17 protein. Our study provides novel insight
into the molecular effects of MPV17 mutations and opens novel possibilities for testing
therapeutic strategies for a devastating group of disorders.
Keywords: Mpv17 mutations, mitochondrial depletion syndrome, mitochondrial dysfunction, protein mislocation,
neurode generation
INTRODUCTION
Mitochondrial DNA depletion syndromes (MDDS) are autosomal recessive disorders characterized
by a severe decrease in mitochondrial DNA (mtDNA) copy number in affected tissues. MDDS
are one of the most common forms of childhood respiratory chain deficiencies (Sarzi et al.,
2007a; Yamazaki et al., 2014). The clinical presentation can be very heterogeneous, with
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overlapping phenotypes, but MDDS are usually classified
as purely myopathic, hepatocerebral, encephalomyopathic,
and neurogastrointestinal (Suomalainen and Isohanni, 2010;
Spinazzola, 2011).
Several genes are associated with MDDS, affecting mtDNA
maintenance by three possible mechanisms: (i) impaired
mitochondrial nucleotide (dNTP) synthesis [mutations in TK2
(Saada et al., 2001), SUCLA2 (Elpeleg et al., 2005), SUCLG1
(Ostergaard et al., 2007), RRMB2 (Bourdon et al., 2007),DGUOK
(Mandel et al., 2001), TYMP (Nishino et al., 1999), ABAT
(Besse et al., 2015), SLC25A4 (Echaniz-Laguna et al., 2012),
and AGK (Mayr et al., 2012)]; (ii) deficient mtDNA replication
[mutations in POLG (Naviaux et al., 1999), POLG2 (Young
et al., 2015), TWINKLE (Sarzi et al., 2007b), TFAM (Stiles
et al., 2016), RNASEH1 (Reyes et al., 2015), MGME1 (Kornblum
et al., 2013), and DNA2 (Ronchi et al., 2013)], which leads
to defects in mtDNA synthesis and repair; or (iii) defective
mitochondrial dynamics [OPA1 (Amati-Bonneau et al., 2008),
MFN2 (Rouzier et al., 2012), and FBXL4 (Antoun et al.,
2015)]. All these mechanisms cause deficient turnover and/or
segregation of mtDNA to daughter cells, leading to a decrease
in its copy number. Ultimately, mtDNA depletion results
in inadequate synthesis of respiratory chain complexes with
consequent deficient energy production and organ dysfunction
(Sarzi et al., 2007a; Spinazzola et al., 2009).
MPV17 is one of the genes associated with the hepatocerebral
form of MDDS (MTDPS6; NNH; MIM #256810). To date, ∼100
affected individuals have been reported with MPV17-related
disease, with a total number of 48 MPV17 pathogenic variants
described (Karadimas et al., 2006; Spinazzola et al., 2006, 2008;
Nogueira et al., 2007; Wong et al., 2007; Navarro-Sastre et al.,
2008; Kaji et al., 2009; Parini et al., 2009; El-Hattab et al., 2010,
2018; AlSaman et al., 2012; Merkle et al., 2012; Mendelsohn et al.,
2013; Uusimaa et al., 2013; Bijarnia-Mahay et al., 2014; Choi et al.,
2015; Dalla Rosa et al., 2016; Kim et al., 2016).
Despite some clinical heterogeneity, the most common
clinical manifestations in patients harboring mutations
in MPV17 are infantile-onset hepatic and neurologic
manifestations, with cerebral leukoencephalopathy in brain
MRI and metabolic abnormalities, including lactic acidosis.
Progressive liver failure is frequently the cause of death in
early childhood. More rarely (around 4%), MPV17 mutations
have also been associated with late-onset neuromyopathy with
multiple mtDNA deletions in skeletal muscle with minimal or no
hepatic disease (Blakely et al., 2012).
The human MPV17 gene encodes a 176 amino acid protein
of 18 kDa. MPV17 was previously thought to be a peroxisomal
protein (Zwacka et al., 1994) but was later found to localize
in the inner mitochondrial membrane (El-Hattab et al., 2018).
Although the function of MPV17 and the mechanisms leading to
mtDNA dysfunction are still unclear, MPV17 was described as a
non-selective channel that modulates mitochondrial membrane
potential (19m) (Antonenkov et al., 2015). Several factors
regulate the gating properties of this putative channel, which
is maintained closed in normally functioning mitochondria
(Antonenkov et al., 2015). In damagedmitochondria, theMPV17
channel is prone to be fully open. Some point mutations in
MPV17 are also predicted to produce a leaky channel, unable
to maintain a high (normal) 19m. Furthermore, loss of MPV17
function causes a total loss of channel activity, increasing 19m
(Antonenkov et al., 2015). In both cases there is excessive ROS
production (Binder et al., 2011; Zorov et al., 2014). Loss of
MPV17 function results in failure of oxidative phosphorylation
(OXPHOS) and in mtDNA depletion in affected individuals
(Karadimas et al., 2006; Wong et al., 2007; Uusimaa et al., 2013).
In MPV17−/− mice (Viscomi et al., 2009) a reduced rate of
mtDNA replication has been observed, due to dNTP insufficiency
(Dalla Rosa et al., 2016).
To better understand the role of MPV17 in human disease,
we investigated the effect of MPV17 knockdown in human cell
lines and characterized the effect of selected MPV17 mutations




Human MPV17 cDNA (a kind gift from Prof. M. Zevianni,
Milano, Italy) was cloned with an HA C-terminal tag, in
pcDNA3.1 (Invitrogen) as previously described (El-Hattab
et al., 2018). The MPV17 mutations were generated by site-
directed mutagenesis using the QuickChange R© Kit (Stratagene).
The sequences of the primers used for mutagenesis are
shown in Supplementary Table 1. Mutagenesis was confirmed
by Sanger sequencing (Supplementary Material 2). MPV17-
specific shRNA-pLKO plasmid (clone ID TRCN0000129921;
Santa Cruz Biotechnology) was used to knockdown the
expression of MPV17 in cell lines.
Cell Culture and Transfections
Cell lines were cultured in DMEM (Dulbecco’s modified
Eagles’s medium) (Invitrogen) supplemented with 10% (v/v)
FBS (fetal bovine serum), 10 U/mL penicillin and 100µg/mL
streptomycin at 37◦C, in a 5% CO2 humidified incubator.
HEK293T knockdown cell line was supplemented with 2.5mM
pyruvate and 0.2mM uridine. Cells were transiently transfected
with the different constructs using FuGENE R©6 transfection
reagent (Roche), according to the manufacturer’s instructions.
Subcellular Fractionation
Standard methods were used to prepare total cell lysates,
mitochondrial, and post-mitochondrial fractions from cultured
cells. In brief, cells were harvested, washed, and resuspended in
MIB (Mitochondrial Isolation Buffer [225mM mannitol, 75mM
sucrose, 10mM MOPS, 1mM EGTA, 0,5% BSA, pH 7.2]. Cells
were homogenized with a glass Pyrex homogenizer (type B pestle,
30 strokes). Unbroken cells, large plasma membrane and nuclei
were removed by two centrifugations at 1,000 × g for 10min.
The resultant supernatant was again centrifuged at 8,000 × g for
15min at 4◦C to separate themitochondrial fraction (pellet) from
the cytosolic fraction (supernatant). Mitoplasts were isolated
from mitochondria by digitonin treatment (Gallet et al., 1999).
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Western Blot Analysis
Protein extracts were separated in 15% SDS-polyacrylamide gel
and transferred to nitrocellulose membranes. Equal amounts
of protein were loaded - 80 µg for whole cell homogenate
and for endogenous MPV17, 50 µg for mitochondria, 50 µg
mitoplasts. Protein concentration was determined using BCA
Kit (Pierce). Primary antibodies used were: goat polyclonal
anti-MPV17 antibody (1:250, SantaCruz Biotechnology), anti-
HA (1:1000, SantaCruz Biotechnology), and anti-Complex IV
(1:5000, Invitrogen). The secondary antibodies were developed
using ECL kit (Bio-Rad) and band intensities were quantified
using ImageJ software.
Viral Production
The shRNA was co-transfected with the packaging plasmid
pCMV-dR8.9 (Addgene) and envelope plasmid pCMV-VSV-G
(Addgene) using FuGENE R©6 transfection reagent (Roche). Non-
specific shRNA-pLKO plasmid was used as control. Infection of
293T cells using lentivirus was performed by exposing cells to
the virus-containing medium and incubating for 4 h. Cells were
maintained under selection conditions with puromycin. Stable
knockdown cell lines were periodically checked by standard
Western blotting, using MPV17 antibody. Rescue studies in
MPV17 knockdown cells were carried out by overexpression of
HA-tagged constructs of wild-type MPV17 and mutant MPV17
cDNA obtained by mutagenesis.
Real-Time Quantitative PCR Analysis of
Mitochondrial DNA Content
The relative mtDNA copy number was evaluated using
quantitative real-time PCR (qRT-PCR). In brief, DNA samples
were diluted to 0.4 ng/µL using Tris-EDTA buffer solution. For
each sample, two primer pairs were used to amplify the tRNA
Leu(UUR) gene - mtDNA and ß-2-microglobulin (ß2M) gene
- nuclear DNA, in separate wells. The primers sequences and
qRT-PCR amplification conditions were previously described
(Venegas et al., 2011). The amplification for each sample was
performed in a final volume of 10 µL, using the 2× SYBR
SuperMix (iTaq SYBR Green Supermix with ROX, BioRad) and
the primer concentration used was 5µM. All samples were run
twice, in triplicate for both mitochondrial and nuclear genes
using 7500 Fast Real-time PCR system (qRTPCR; PE7500 real-
time PCR instrument; Applied Biosystems, Foster City, CA,
USA). A negative and a positive control were also included
in each run in order to verify possible contaminations and
to act as intern calibrator of values, respectively. Standard
deviations for the cycle of threshold value were accepted at
0.50. The results were analyzed with the 7500 R© v2.0.4 software
(Applied Biosystems).
Confocal Microscopy
Cells were grown to around 60% confluency on glass coverslips
coated with poly-D-lysine (Sigma). Cells were then sequentially
incubated with medium containing 200 nM MitoTracker Red
CMXRos (Molecular Probes), fixed in 4% paraformaldehyde
(PFA), permeabilized with 0.1% Triton-100, blocked in 10%
normal goat serum and incubated with primary anti-HA
antibody (1:100, SantaCruz Biotechnology). Next, cells were
incubated with conjugated secondary antibody anti-rabbit Alexa
Fluor 488 (1:1000, Invitrogen) and DAPI. Images were captured
in a Zeiss LSM 510 META confocal microscope (Carl Zeiss) with
63x/1.4 oil immersion objective. Acquisitions were made using
the MetaMorph software (Universal Imaging). The images were
analyzed in ImageJ.
Cellular Metabolic Activity Studies
Cellular metabolic activity was used as a measure of viability
and was determined using resazurin (Sigma-Aldrich, St. Louis,
Missouri, USA) assay in 96-well plates. Fluorescence intensity
was measured (excitation 560 nm, emission 590 nm) in a
microplate reader Tecan Infinite R© 200 (Tecan, MÄnnedorf,
Switzerland). The release of lactate dehydrogenase (LDH) into
the culture media was used as a measure of cytotoxicity, and
was performed according to the manufacturers’ instructions
(Sigma-Aldrich).
Mitochondrial Respiration Studies
Wildtype (control) and MPV17-knockdown HEK293T
cells were grown in standard conditions. KD cell line was
supplemented with 2.5mM pyruvate and 0.2mM uridine. The
assay was performed in the Seahorse Bioscience XF24. Oxygen
Consumption Rate (OCR) and Extra-Cellular Acidification Rate
(ECAR) measurements were measured under basal conditions
and after the sequential injection of 1µg/ml oligomycin, 0.5µM
of FCCP and 1µM rotenone/antimycin A, allowing for the
estimation of basal respiration, proton leak, maximal respiration
rate, spare respiratory capacity and ATP production (Tan
et al., 2004). ATP production is calculated from the decrease
in respiration rate when ATPase activity is blocked, meaning
the difference between de OCR before and after oligomycin
injection. Proton leak is the respiration that remains after
ATPase activity inhibition by oligomycin minus the non-
mitochondrial respiration. Maximal respiration rate (MRR)
is the difference between maximal mitochondrial respiration
measured as OCR in mitochondrial uncoupled by FCCP and the
non-mitochondrial OCR measured in mitochondrial exposed
to rotenone/antimycin A. Spare respiratory capacity (SRC), an
indicator of the bioenergetics capacity, is the difference between
OCR-F and OCR-B. The respiratory control ratio (RCR) is an
index of mitochondrial coupling and is calculated as the ratio
between the OCR-F and OCR-O.
ROS Measurement
The total ROS content of cells was assessed using 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCF-DA).
Fluorescence intensity was measured (excitation 495 nm,
emission 527 nm). Mitochondrial superoxide production was
monitored using the superoxide-sensitive probe MitoSOXTM
Red (Molecular Probes). Fluorescence intensity was measured
(excitation 510 nm, emission 580 nm). A microplate reader
Tecan Infinite R© 200 (Tecan, MÄnnedorf, Switzerland) was used.
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Measurement of Mitochondrial Membrane
Potential (19m)
Mitochondrial membrane potential was measured using JC-1
probe (Invitrogen), according to manufacturer’s protocol.
Fluorescence intensity was measured (excitation 560 nm,
emission 595 nm for J-aggregates in healthy cells and excitation
485 nm, emission 535 nm for monomers in apoptotic cells) in
the microplate reader Tecan Infinite R© 200 (Tecan, MÄnnedorf,
Switzerland). The ratio of fluorescent intensity of J-aggregates to
fluorescence intensity of monomers was used as an indicator of
cell health.
Lactate and Pyruvate Measurement
L-lactate and pyruvate were measured in the culture medium
with L-Lactate Assay Kit (Abcam, #ab65330) and Pyruvate Assay
Kit (Abcam, ab65342), respectively, in 96-well plates, according
to the manufacturer’s instructions.
Statistics
Statistical analyses were performed with GraphPad Prism
(Version 7.0). One-way ANOVA test with Bonferroni post-hoc
test were performed as shown. Values are plotted as the mean
± SD. p-Values are based on the following pattern: ns (not
significant; p> 0.05), ∗ (significant; p< 0.05), ∗∗ (significant; p<
0.01), and ∗∗∗ (significant; p < 0.001).
RESULTS
Reduction of MPV17 Protein Levels Affect
Cell Metabolic Activity
To investigate the molecular effects of MPV17 loss of function,
we developed a cellular model to analyse protein content,
subcellular localization and mitochondrial bioenergetics. We
assessed the endogenous levels of MPV17 in three different cell
lines by immunoblotting analyses. The protein was expressed
at similar levels in HEK293T, H4, and HepG2 (Figure 1A). To
generate an MPV17 knockdown (MPV17KD) cell line, we used
a lentiviral vector encoded shRNA. In parallel, we generated
a control cell line using a scrambled shRNA sequence. In
the KD cells, the levels of MPV17 were efficiently reduced
when compared to the control cells (Figure 1B). We restored
MPV17 levels in the MPV17KD cell line by transfecting wild-
type MPV17 (Figure 1C; Supplementary Figure 3). Next, we
assessed the metabolic activity of cells knocked down for MPV17
using the resazurin reduction assay. Under basal conditions,
MPV17KD cells showed decreased resazurin reduction by 38.5%
when compared to control. As resazurin reduction can be
used as a measure of cell viability but also as an indicator
of overall mitochondrial function, this indicates MPV17KD
reduced cell viability and/or deficient mitochondrial oxidative
capacity, as differences in cell proliferation were not detected
by cell count (Figure 1D). Mitochondrial DNA (mtDNA)
determination, using RT-qPCR, in MPV17KD cells showed no
significant difference when compared to cells expressing wild-
type levels of MPV17 (Figure 1E).
Reduction of MPV17 Protein Levels
Decreases Mitochondrial Bioenergetics
To understand how MPV17 knockdown affects mitochondrial
function, we analyzed the cellular respiratory profile using
a Seahorse Flux Analyser, through the successive addition
of oligomycin, FCCP and rotenone/antimycin A to block
mitochondrial electron transport chain. In control conditions,
oxygen consumption rate (OCR-B) is inhibited when ATP
synthesis is blocked by oligomycin (OCR-O) and is stimulated
when oxidation is uncoupled from phosphorylation by FCCP
(OCR-F). OCR-B, -O, and –F were significantly lower (p
< 0.001) in the MPV17KD cells when compared with the
control (Figures 2A,B). Values of OCR-B, -O, and -F were
used to calculate other bioenergetics parameters, i.e., proton
leak, maximal respiration rate (MRR), spare respiratory capacity
(SRC), and estimate ATP production (Figure 2C). MRR, SRC,
and ATP production were all significantly lower in the mutant
cells when compared with control. Overall, these results indicate
decreased mitochondrial bioenergetic capacity in MPV17KD
cells. Despite the slightly lower ECAR in basal conditions
(Figures 2D,E), in stressful conditions (by the addition of
oligomycin and FCCP) MPV17KD cells showed lower ECAR
when compared with WT (CTRL) cells. OCR-B/ECAR ratio was
decreased in MPV17KD cells (Figure 2F), and the bioenergetic
map that plots OCR against ECAR reveal a limited glycolytic
capacity of KD cells when compared with control. Overall, these
results suggest that loss of MPV17 causes significant impairment
in mitochondrial respiratory capacity and limited metabolic
capacity to meet high energy demand (Figure 2G).
MPV17 Mutants Maintain Mitochondrial
Localization but Are Less Stable Than WT
Protein
To investigate the effect of selected disease-associated mutations,
we expressed MPV17 mutants in MPV17KD cells. Considering
the clinical criteria, and in silico analysis of the predicted
effects of the amino acid substitutions, we selected five MDDS-
related mutations for in depth molecular studies: arginine to
glutamine substitution at position 50 (MPV17R50Q) which is the
most frequent mutation; arginine to tryptophan substitution at
position 50 (MPV17R50W) which usually associates with Navajo
neurohepatopathy with a severe clinical prognosis; deletion of
three amino acids encoding for Gly79_Thr81 (MPV1779−81del)
which are predicted to delete a putative kinase C phosphorylation
site; substitution of glycine for an arginine at position 94
(MPV17G94R) in the first amino acid of exon 5 which has a
possible effect on splicing; and a substitution of a serine for
phenylalanine at position 170 (MPV17S170F), localized at the C-
terminal of the protein and possibly abolishes a phosphorylation
site (Supplementary Material 2) Wild-type HA-tagged MPV17
(MPV17WT) was used as control.
To determine whether MPV17 mutations affect the
subcellular localization of the protein, HEK293T knockdown
cells were transfected with the various constructs and imaged
using confocal microscopy. As expected, HA-tagged MPV17WT
displayed a punctate distribution in the cytoplasm that
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FIGURE 1 | Expression of MPV17 in different cell lines. (A) Immunoblotting showing MPV17 endogenous expression in different human cell lines (HEK293T, H4 and
HepG2) and (B) knockdown of MPV17 using shRNA system (shMPV17), when compared with shRNAcontrol (CTRL). NT - cells without any treatment. (C) Western
blot showing that expression of MPV17-HA protein restores the protein levels in the different cell lines used. An anti-MPV17 antibody was used to detect endogenous
MPV17 protein in mitochondrial fraction in three human cell lines. Anti-COX-IV antibody was used as a mitochondrial marker. Cells are plated at the day before
experiments so that cells will be ∼60% confluent on the day of transfection. Cells are analyzed 24 h after transfection (D) Effect of MPV17 knockdown on resazurin
reduction capacity as a measure of metabolic activity. Wild-type HEK293T cells were used as control (CTRL) Cells were platted as 2 × 104 cells/well and cultured for
48 h. (E) Effect of MPV17 knockdown on mtDNA copy number, determined by RT-qPCR. n = 3. *p < 0.05. Bars indicate the standard deviation (SD).
colocalized with the mitochondrial marker. Additionally, we
observed mitochondrial localization for all mutant proteins,
except for the MPV17G94R mutant. In cells expressing the
MPV17G94R mutant protein, the mitochondria network was
ill-defined or not staining with MitoTracker Red CMXRos,
a 19m-sensitive dye (Tan et al., 2004). These mitochondria
devoid of Mitotracker staining coexisted side by side with
non-transfected cells with normal mitochondria staining. These
results suggested that the MPV17G94R mutation induced the
dissipation of 19m in the transfected cells (Figure 3A).
Although themutations did not affect mitochondrial targeting
of the protein, we hypothesized that they might affect the
localization of the protein inside the mitochondria. To test
this, we performed subcellular localization studies in cells
expressing the different MPV17 variants. Both WT and mutant
protein were enriched in the mitochondrial fraction (Figure 3B).
However, MPV17 levels were markedly decreased for all mutants,
especially for MPV1779−81del, MPV17G94R, and MPV17S170F
(<10% of levels found in MPV17WT) (Figure 3C). Mitoplasts
were obtained by removing the mitochondrial outer membrane
from isolated mitochondria. As expected, wild-type protein
(MPV17WT) was found in mitoplasts, consistent with its
inner mitochondrial membrane localization. In the presence of
MPV17G94R mutation, the mutant protein was not found in the
mitoplast fraction (Figure 3D). All other mutations had no effect
on the localization of the protein. To investigate if the reduced
levels of mutantMPV17 protein were a consequence of decreased
transcription, mRNA levels were assessed by RT-qPCR. When
compared with WT, mutants mRNA levels are lower particularly
for G94R but also for R50W and S170F mutants (Figure 3E),
suggesting a compromised transcription for these mutants. The
G94R mutant is mislocalized as well as transcribed at low levels
when compared with the WT protein.
MPV17 Mutations Affect Mitochondrial
Function and the Metabolic Capacity of the
Cells
To further understand how mutations in MPV17 result in
mitochondrial dysfunction, MPV17KD cells were transfected
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FIGURE 2 | MPV17KD cells display reduced bioenergetics capacity. (A) OCR profile in HEK293T (CTRL) and knockdown (MPV17KD) cell lines. OCR expressed as
pMolesO2/min. Vertical lines indicate the time of addition of oligomycin (Oligo), FCCP and rotenone/antimycin A, reflecting OCR-B, -O, and –F, respectively. MPV17KD
cells are particularly insensitive to FCCP, indicating lower reserve respiratory capacity. (B) OCR in basal conditions, OCR-O, OCR-F, and OCR-R. (C) Individual
bioenergetics parameters with maximal respiration rate (MRR), spare respiratory capacity (SRC) and ATP production. (D,E) ECAR profile in CTRL and MPV17KD cells.
The glycolytic activity after respiratory chain disruption with oligomycin and FCCP addition is lower in MPV17KD cells than in control, expressed as lower ECAR. (F)
Lower OCR-B/ECAR in MPV17KD cells, reflecting insufficient increase in the rate of glucose utilization via anaerobic glycolysis to compensate mitochondrial respiratory
deficiency. (G) Bioenergetic map of OCR-B/ECAR. The quadrants were set at arbitrary values to indicate only the direction of bioenergetics changes. All
determinations were performed in 11 replicates for each cell line and the values were calculated after normalization to the final cell number and are plotted as the
mean ± SD. ANOVA test for controls vs. MPV17KD. ***p < 0.001.
with either wild-type (WT) or mutant forms of MPV17.
Several parameters of mitochondrial function were assessed.
We first determined whether MPV17 mutations affected
cell viability/proliferation. Although we cannot completely
exclude that this might be explained by differences in cell
proliferation (which we could not detect by comparing cell
numbers), cytotoxicity measured by LDH release did not account
for the differences observed (Figure 4A). Cells expressing
R50W, G79-T81del, and G94R mutations displayed decreased
resazurin reduction capacity (Figure 4B). As mentioned before,
this suggests either decreased cell viability and/or deficient
mitochondrial oxidative capacity. Mitochondrial membrane
potential (19m) is a key parameter of mitochondrial function
and a useful indicator of cell viability. As suggested by
microscopy experiments, the MPV17G94R mutation appears
to cause the loss of mitochondrial membrane potential. In
steady-state cells, only the MPV17S170F mutation seemed
to cause significant loss of 19m, as seen by decreased
J-aggregates/monomers (red/green fluorescence) ratio when
comparedwith cells expressing wild-type protein (Figure 4C). To
investigate the effect of the various MPV17 forms on glycolytic
activity, we measured the levels of lactate, pyruvate and the
lactate/pyruvate ratio. Mutations inMPV17 were associated with
increased dependence on glycolytic ATP production (Figure 4D)
and showed decreased mitochondrial competency, as evaluated
by the resazurin assay. Cells expressing the MPV17R50W
mutation showed an 8-fold increase in lactate levels when
compared with control cells. These differences in lactate levels
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FIGURE 3 | Expression and subcellular localization of MPV17 mutants. (A) Confocal microscopy images demonstrating that MPV17WT (green) is distributed
throughout the cytoplasm, and colocalizes with MitoTracker Red (red) in HEK293T transfected cells, indicating mitochondrial localization of the protein. In MPV17G94R
expressing cells, mitochondria do not stain with specific dye Mitotracker Red. Like wild-type protein, all other mutated versions of the protein, are localized in the
mitochondria. Scale bar = 20µm. (B) Representative immunoblotting of expression of MPV17-HA protein in HEK293T cells. (C) Quantitative histogram of both
wild-type and mutant MPV17 protein enriched in mitochondrial fraction. All MPV17 mutant proteins have lower expression levels when compared with wild-type. (D)
MPV17G94R was not found in mitoplast, indicating abnormal localization inside the mitochondria. The intensity of the bands of Western blot, for each condition, and all
the mutants were normalized by the intensity of the MPV17WT (our control). LDH and COX-IV were used as cytosolic and mitochondrial markers, respectively. (E) The
mRNA levels of MPV17 wild type and mutant genes were quantified by RT-qPCR. Values are reported as mRNA levels normalized respect to WT. Expression was
normalized to the mRNA levels of the internal control actin (ACT1) (n = 3). ANOVA test for mutants vs. MPV17WT, bars indicate the standard deviation (SD), *p < 0.05
and ***p < 0.001.
were not accompanied by significant differences in pyruvate.
LDH activity did not explain the differences in lactate levels
between the samples (Figure 4A). Mitochondria are the major
source of ROS in the cell, as a byproduct of the oxidative
phosphorylation (OXPHOS) process. Thus, we assessed the
possible effect of MPV17 mutations on intracellular ROS levels.
We used the DCFH-DA dye in order to measure ROS levels in
cells, and MitoSOX to evaluate mitochondrial superoxide (O•2)
levels. Cells expressing most MPV17 mutants showed a tendency
toward elevated levels of intracellular ROS when compared
with control cells. In the case of mitochondrial superoxide, this
difference was detectable both in basal conditions (with the
exception of cells expressing MPV17R50W and MPV17S170F) and
in H2O2-induced stress conditions (Figure 4E).
DISCUSSION
MPV17 is a non-selective channel of the inner mitochondrial
membrane. Its exact function as well as the mechanism
leading to mtDNA instability is unknown. To gain insight
into the molecular mechanisms associated with disease in
patients carrying MPV17 mutations, we evaluated the cellular
consequences of MPV17 deficiency.
Lack of functional MPV17 protein in mitochondria
may initiate tissue-specific cell-death and degeneration
(Meyer zum Gottesberge and Felix, 2005). Our experiments
indicate that MPV17KD cells exhibited reduced viability
while proliferation was not affected (Figure 1D)
(O’Brien et al., 2000).
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FIGURE 4 | Cells expressing MPV17 mutants display mitochondrial dysfunction. MPV17WT and MPV17 mutants analyzed after 48 h post-transfection. HEK293T cells
were used as control (CTRL). (A) No difference in cell death was observed by LDH release assay in mutants when compared with MPV17WT. (B) All mutants showed
decreased capacity to reduce resazurin, in particular MPV17R50W, MPV1779−81del, and MPV17G94R mutants, when compared with cells expressing MPV17WT. (C)
Mitochondrial membrane potential measured with JC1-probe. MPV17S170F mutation caused steady-state 19m loss when compared with wild-type protein. (D)
Lactate and pyruvate measurements in 293T cells expressing the five mutants. Lactate and pyruvate levels were normalized for protein (n = 5) and expressed as
fold-change relative to control. (E) Intracellular ROS and mitochondrial superoxide levels measured with DCF and MitoSOX probes, respectively, are higher in MPV17
mutants when compared with control. Stress challenge was performed by culturing cells with H2O2 50µM for 2 h. Values represent fluorescence intensity relative to
protein levels. Statistics were determined by one-way ANOVA with Bonferroni post-hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001.
In the absence of MPV17, cells exhibit decreased oxygen
consumption, indicating respiratory chain and OXPHOS
impairment. Extracellular acidification rate (ECAR) is a
surrogate measure of the production of lactic acid and, therefore,
an indicator of anaerobic glycolysis. The OCR-B/ECAR ratio
indicates the balance between mitochondrial respiration
(OXPHOS) and glycolysis.
Frequently, defects in the former are associated with
compensatory increase in the latter. As expected, OCR-B/ECAR
ratio was decreased in MPV17KD cells, reflecting impaired
mitochondrial respiratory capacity and limited glycolytic
capacity (Figures 2F,G). However, and contrary to our initial
expectations, stress-induced ECAR in MPV17 deficient cells
were lower than in control cells, reflecting an energetic quiescent
metabolic profile. These results are consistent with those already
observed inMPV17−/− murine podocytes (Casalena et al., 2014)
that showed ≈40% reduced ECAR when compared with wild-
type. This is compatible with a role of MPV17 in mitochondrial
homeostasis and may indicate that MPV17 is important for
the activation of compensatory mechanisms in situations of
impaired OXPHOS.
To date, almost 50 pathogenic mutations have been associated
with MPV17-related MDDS. Here, we describe metabolic
parameters in five cell lines expressing MPV17 mutations,
which enable the study of protein levels, localization, and
effects on overall bioenergetics. Although no clear genotype-
phenotype correlation currently exists, some mutations carry a
better prognosis, implying that different mutations may cause
distinct consequences in MPV17. Our findings demonstrate
that all mutations affect the levels of the MPV17 protein
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(Figure 3B). Using two different techniques, we show that the
MPV17 mutations studied do not affect proper targeting of
the protein to the mitochondria (Figures 3A,C). Nevertheless,
MPV17G94R behaved differently, as this mutant protein is found
in mitochondrial enriched extract but it is not detected in the
mitoplast (Figure 3D), reflecting that G94R mutation abolishes
protein localization in the inner mitochondrial membrane.
Although further studies are needed, one possible explanation
is that the mutant protein probably is retained in the
intermembrane space (IMS) or is loosely attached to the outer
mitochondrial membrane (OMM).
In normally functioning mitochondria, the MPV17 channel
is closed (Antonenkov et al., 2015). Nevertheless, the gating
properties of the channel are modified by membrane potential,
phosphorylation status and redox state. The regulation of
the 19m is vital to sustain mitochondrial homeostasis, as
many functions like mitochondrial biogenesis, dynamics, ROS
production and mitophagy depend on it. The MPV17G94R
mutation affects 19m as seen in microscopy studies using the
Mitotracker Red dye. The fact that this was not obvious with the
use of JC-1, another probe for measuring 19m, is not clear, but
might be due to different sensitivity of this probe, especially in
the context of a heterogeneous population of transfected cells.
The new findings regarding the effect of the G94R mutation
suggests that mislocalization of MPV17 may induce MPV17
dysfunction. Moreover, together with loss of membrane potential
we reasoned that this affects the protein function and is likely to
play a major role in MPV17 disease in patients affected by this
particular mutation.
Mutations in phosphorylation sites are responsible for several
neurodegenerative disorders, including MDDS cases (Uusimaa
et al., 2013). The amino acid sequence of the MPV17 protein
has three predicted phosphorylation sites (Thr53, Thr80, and
Ser170), and mutations in all three were found to cause
MDDS. Studies employing mutants that mimic phosphorylated
and unphosphorylated forms of the protein indicate that
phosphorylation of MPV17 may lead to a complete closing of
the channel, particularly in reducing conditions (Antonenkov
et al., 2015). We demonstrate that MPV17S170F causes a lower
steady-state 19m. However, MPV1779−81del, a mutation that
also abolishes a phosphorylation site, does not appear the
affect 19m (Figure 4C). Together, this suggests that mutations
on phosphorylation sites do not have a uniform pathogenic
effect on the protein. Second, cells expressing the MPV17S170F
display lower ROS levels when compared with other mutants
(Figure 4E). We hypothesize that the mutation creates a “leaky”
MPV17 channel, unable to stay completely closed to preserve
a normally high 19m. At the same time, this may also reflect
some intact compensatory mechanisms to prevent excessive
ROS accumulation.
Mitochondrial DNA and proteins are particularly sensitive to
ROS as they are located in close proximity to the respiratory
chain. Except for MPV17S170F, all mutants have increased levels
of mitochondrial ROS (superoxide) production. However, this
increase is only significant in MPV1779−81del and MPV17G94R
mutants. We interpret this as a common end-stage effect of
different mutations, independently of the exact mechanisms by
which each mutation leads to protein dysfunction. A cascade
of negative effects of ROS on mtDNA stability and OXPHOS
function is expected and, therefore, a common clinical phenotype
of the MPV17-associated MDDS.
Although the molecular implications of our findings in
simple cell systems may not be straightforward, the cellular
abnormalities identified inform on possible cellular pathologies
taking place. We hypothesize the effects of the mutations might
be even larger in such tissues, given their high energy demand,
increased number of mitochondria and dependence of OXPHOS
for ATP supply.
In conclusion, we demonstrate that MPV17 mutations can
cause respiratory chain impairment by different mechanisms,
including increased ROS production, decreased oxygen
consumption, potential dissipation and sub-mitochondrial
mislocalization. For each mutation, isolated or several
simultaneous mechanisms may contribute to a cumulative
deleterious effect that leads to disease. Future studies, based on
our findings, will inform on the best strategy for targeting the
effects of MPV17 mutations in MDDS.
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